Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Revolution Medicines, Inc. is set to present nine oral and poster presentations at the AACR Annual Meeting, showcasing advancements in its RAS(ON) inhibitor pipeline for RAS-addicted cancers [1][4] Presentation Highlights - New Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a plenary session, focusing on patients with previously treated KRAS G12D mutant non-small cell lung cancer [2] - Two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, will be presented, including monotherapy and combination therapy data with chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma [3] - Additional presentations will cover preclinical research on a new class of mutant-targeted catalytic RAS(ON) inhibitors, aimed at maintaining antitumor activity despite resistance [4] Presentation Details - An invited presentation titled "Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors" will be given by Dr. Mallika Singh on April 18 [6] - An oral presentation on the preliminary safety and clinical activity of zoldonrasib will be presented by Dr. Jonathan Reiss on April 19 [7] - A mini-symposium will feature daraxonrasib plus chemotherapy as a first-line treatment for metastatic pancreatic adenocarcinoma, presented by Dr. Brian Wolpin on April 21 [8] - Additional poster presentations will cover various aspects of RAS(ON) inhibitors and their effects on cancer and immune cells [10] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors currently in clinical development [12]